Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 183

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 183
---
 Specifically, due to the large unmet medical need, global
demographics and relatively attractive reimbursement dynamics, the oncology market is fiercely competitive and there are a number of large
pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates
for the treatment of cancer. Our competitors may succeed in developing, acquiring or licensing technologies and drug products that are
more effective, have fewer or more tolerable side effects or are less costly than any product candidates that we are currently developing
or that we may develop, which could render our product candidates obsolete and noncompetitive.

41

We rely on key personnel and, if we are
unable to retain or motivate key personnel or hire qualified personnel, we may not be able to grow effectively.

We are dependent on certain
members of our management, the loss of services of one or more of whom could materially adversely affect us. In particular, our success
depends to a significant extent upon the continued services of Dr. Raymond J. Tesi, our President and CEO. Dr. Tesi has overseen INmune
Bio since inception and provides leadership for our growth and operations strategy as well as being an inventor of our patents. Although
we have entered into an employment agreement with Dr. Tesi, if he were to nevertheless terminate his employment with us, the loss of the
services of Dr. Tesi, would have a material adverse effect on our growth, revenues, and prospective business. We are also highly dependent
on the other principal members of our management and scientific team. We are not aware of any present intention of any of our key personnel
to leave our company or to retire. The loss of any of our key personnel, or the inability to attract and retain qualified personnel, may
significantly delay or prevent the achievement of our research, development or business objectives and could materially adversely affect
our business, financial condition and results of operations.

Our ability to manage growth
effectively will require us to continue to implement and improve our management systems and to recruit and train new employees. There
can be no assurance that we will be able to successfully attract and retain skilled and experienced personnel.

Product liability lawsuits against us could
divert our resources, cause us to incur substantial liabilities and limit commercialization of any products that we may develop.

We face an inherent risk of
product liability claims as a result of the clinical testing of our product candidate despite obtaining appropriate informed consent from
our clinical trial participants. We will face an even greater risk